Salmon calcitonin in the prevention and treatment of osteoporosis

Trends in Endocrinology and Metabolism

Volumn 8, Issue 3, 1997, Pages 89-92

  Avioli, Louis V ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; NOSE SPRAY; SALCATONIN;

ANALGESIC ACTIVITY; BONE DENSITY; CLINICAL TRIAL; DRUG FORMULATION; ESTROGEN THERAPY; FLUSHING; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030982760     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(97)00015-5     Document Type: Article

References (26)

1. Agnusdei D, Gonnelli S, Camporeale A, et al.: 1989. Efficacia clinica di un trattamento con calcitonina di salmone, somministrata per via endonasale per un anno, nell'osteoporosi postmenopausale stabilizzata. Minerva Endocrinol 14:169-176.
2. 47calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clin Sci 38: 397-407.
3. Civitelli R, Bonnelli S, Zacchei F, et al.: 1988. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268-1274.
4. Devogelaer JP, Broll A, Correa-Rotter R, et al.: 1996. Oral alendronate induces progressive increase in bone mass of the spine, hip and total body in postmenopausal women with osteoporosis. Bone 18:141-150.
5. Ellerington MC, Hillard TC, Whitcroft SU, et al.: 1996. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 59:6-11.
6. Gennari C, Chierichetti SM, Piolini M, et al.: 1985. Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298-308.
7. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R: 1992. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 50: 381-383.
8. Kanis JA, Johnell O, Gullberg B, et al.: 1992. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:24-28.
9. Kraenzlin ME, Seibel MJ, Trechsel U, et al.: 1996. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 58:216-220.
10. Liberman UA, Weiss SR, Broll J, et al.: 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 333: 1437-1443.
11. Lyritis GP, Tsakalakos N, Magiasis B, et al.: 1991. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 49:369-372.
12. Lyritis GP, Magiasis B, Tsakalakos N: 1995. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 56:38-41.
13. Mazzuoli GF, Passen M, Gennari C, et al.: 1986. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3-8.
14. Mazzuoli GF, Tabolli S, Bigi F, et al.: 1990. Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int 47: 209-214.
15. Meschia M, Brincat M, Barbacini P, et al.: 1992. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 47:53-57.
16. Overgaard K, Riis BJ, Christiansen C, Hansen MA: 1989a. Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 299:477-479.
17. Overgaard K, Riis BJ, Christiansen C, et al.: 1989b. Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol 30: 435-442.
18. Overgaard K, Hansen MA, Jensen SB, Christiansen C: 1992. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305:556-561.
19. Punn KK, Chan LWL: 1989. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205-209.
20. Reginster J-Y: 1991. Effect of calcitonin on bone mass and fracture rates (Suppl 5B), Am J Med 91:19S-22S.
21. Reginster J-Y, Albert A, Lecart MP, et al.: 1987. 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483.
22. Reginster J-Y Denis D, Deroisy R, et al.: 1994. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69-73.
23. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F: 1992. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16: 131-138.
24. Rico H, Revilla M, Hernandez EF, et al.: 1995. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181-185.
25. Roth A, Kolaric K: 1986. Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Oncology 43: 283-287.
26. Szanto J, Jozsef S, Rado J, et al.: 1986. Pain killing with calcitonin in patients with malignant tumors. Oncology 43:69-72.